DUPIXENT is the first and only FDA-approved biologic treatment that directly inhibits IL-4 and IL-13 signaling, two of the key drivers of underlying type 2 inflammation in AFRS1-3,*
*The mechanism of dupilumab action has not been definitively established.1
About AFRS
AFRS is a unique and distinct subtype of CRS, driven in part by type 2 inflamation.4,5
Prevalence
The prevalence of AFRS can vary in the US, with higher occurrence in warm, humid climates.6,7
Symptoms
AFRS signs and symptoms may include nasal polyps, loss of smell, thick mucus discharge,
and bone erosion around the sinus cavities.2,3,8,9
DOSING
The recommended dosage for adults with AFRS is 300 mg Q2W.1
| Weight-based dosage in pediatric patients 6 to 17 years of age with AFRS1 |
|
|---|---|
| Body Weight | Recommended Dosage |
| 15 to <30 kg | 300 mg Q4W |
| 30 to <60 kg | 200 mg Q2W |
| ≥60 kg | 300 mg Q2W |
Consider before injecting
DUPIXENT is administered by subcutaneous injection and is intended for use under the guidance of a
healthcare provider.
- Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT
prior to use, according to the Instructions for Use - Rotate injection site with each injection
- A caregiver or patient may inject DUPIXENT after training in subcutaneous injection technique using the
pre-filled syringe or pre-filled pen
DUPIXENT is also indicated as an add-on maintenance treatment in patients aged 12+
years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)1
WORLDWIDE ACROSS APPROVED
INDICATIONS1,10,a
aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US), with the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, CRSwNP, EoE, PN, COPD, CSU, and BP. Data through December 2025.1,10
AD, atopic dermatitis; BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis; PN, prurigo nodularis; Q2W, once every 2 weeks; Q4W, once every 4 weeks.
QUESTIONS ABOUT
DUPIXENT?
Connect with a Field Representative to discuss questions you may have
about prescribing DUPIXENT to your patients with AFRS.